相似文献
1
Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers.
AAPS PharmSciTech. 2010 Sep;11(3):1147-51. doi: 10.1208/s12249-010-9486-9. Epub 2010 Jul 24.
2
Development and evaluation of nanoemulsion and microsuspension formulations of curcuminoids for lung delivery with a novel approach to understanding the aerosol performance of nanoparticles.
Int J Pharm. 2019 Feb 25;557:254-263. doi: 10.1016/j.ijpharm.2018.12.042. Epub 2018 Dec 28.
3
Effects of flow pattern, device and formulation on particle size distribution of nebulized aerosol.
Int J Pharm. 2019 Apr 5;560:35-46. doi: 10.1016/j.ijpharm.2019.01.025. Epub 2019 Jan 19.
4
Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers.
J Pharm Pharmacol. 2006 Jul;58(7):887-94. doi: 10.1211/jpp.58.7.0002.
5
SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-mesh Nebulizer with a Valved Holding Chamber and a Conventional Jet Nebulizer: a Randomized Cross-over Study.
Pharm Res. 2017 Feb;34(2):290-300. doi: 10.1007/s11095-016-2061-7. Epub 2016 Nov 7.
6
Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol.
Allergol Int. 2013 Mar;62(1):131-5. doi: 10.2332/allergolint.12-OA-0482. Epub 2013 Jan 25.
7
Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers.
Int J Pharm. 2021 Apr 1;598:120376. doi: 10.1016/j.ijpharm.2021.120376. Epub 2021 Feb 20.
8
Droplet aerodynamics, cellular uptake, and efficacy of a nebulizable corticosteroid nanosuspension are superior to a micronized dosage form.
Biotechnol Prog. 2012 Sep-Oct;28(5):1152-9. doi: 10.1002/btpr.1616. Epub 2012 Sep 21.
9
Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization.
J Pharm Sci. 2019 Aug;108(8):2588-2592. doi: 10.1016/j.xphs.2019.03.009. Epub 2019 Mar 15.
10
The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension.
J Aerosol Med. 1999 Summer;12(2):47-53. doi: 10.1089/jam.1999.12.47.
引用本文的文献
1
Nanomaterials in COPD: Emerging Therapeutic and Diagnostic Frontiers with a Focus on Metal-Organic Frameworks.
Int J Mol Sci. 2025 Aug 19;26(16):8025. doi: 10.3390/ijms26168025.
2
Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases.
Pharmaceutics. 2025 Jul 9;17(7):893. doi: 10.3390/pharmaceutics17070893.
3
An Inhaled Nanoemulsion Encapsulating a Herbal Drug for Non-Small Cell Lung Cancer (NSCLC) Treatment.
Pharmaceutics. 2025 Apr 22;17(5):540. doi: 10.3390/pharmaceutics17050540.
4
Black seed oil nanoemulsion containing albendazole against protoscoleces of : An study on C57BL/6 mice.
Iran J Basic Med Sci. 2025;28(6):755-761. doi: 10.22038/ijbms.2025.83014.17942.
5
Preparation of a nanoemulsion containing active ingredients of cannabis extract and its application for glioblastoma: in vitro and in vivo studies.
BMC Pharmacol Toxicol. 2024 Oct 7;25(1):73. doi: 10.1186/s40360-024-00788-w.
6
Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery.
J Aerosol Med Pulm Drug Deliv. 2024 Aug;37(4):202-218. doi: 10.1089/jamp.2024.29117.mk.
7
Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives.
Pharmaceutics. 2024 May 11;16(5):648. doi: 10.3390/pharmaceutics16050648.
8
Poly(malic acid)-budesonide nanoconjugates embedded in microparticles for lung administration.
Drug Deliv Transl Res. 2024 Aug;14(8):2062-2078. doi: 10.1007/s13346-024-01571-4. Epub 2024 Mar 22.
9
Recent Trends and Applications of Nanostructure-based Drug Delivery in Alleviating Chronic Obstructive Pulmonary Disease (COPD).
Curr Drug Deliv. 2024 Mar 5. doi: 10.2174/0115672018289883240226113353.
10
Nanocarrier-Mediated Drug Delivery via Inhalational Route for Lung Cancer Therapy: A Systematic and Updated Review.
AAPS PharmSciTech. 2024 Feb 29;25(3):47. doi: 10.1208/s12249-024-02758-1.
本文引用的文献
1
In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns.
Respir Care. 2009 Dec;54(12):1671-8.
2
Evaluation of supercritical fluid engineered budesonide powder for respiratory delivery using nebulisers.
J Pharm Pharmacol. 2009 Dec;61(12):1625-30. doi: 10.1211/jpp/61.12.0006.
3
Aerodynamic characteristics of nebulized terbutaline sulphate using the Next Generation Impactor (NGI) and CEN method.
J Aerosol Med Pulm Drug Deliv. 2009 Mar;22(1):19-28. doi: 10.1089/jamp.2008.0650.
4
Determination of factors controlling the particle size in nanoemulsions using Artificial Neural Networks.
Eur J Pharm Sci. 2008 Sep 2;35(1-2):42-51. doi: 10.1016/j.ejps.2008.06.002. Epub 2008 Jun 20.
5
The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems.
Expert Opin Drug Deliv. 2005 Mar;2(2):377-90. doi: 10.1517/17425247.2.2.377.
6
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Am J Respir Crit Care Med. 2005 Dec 15;172(12):1497-504. doi: 10.1164/rccm.200410-1414OC. Epub 2005 Sep 28.
7
In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per Aerosol).
Pulm Pharmacol Ther. 2005;18(2):151-3. doi: 10.1016/j.pupt.2004.10.004. Epub 2004 Dec 20.
8
Nanosuspensions: a promising drug delivery strategy.
J Pharm Pharmacol. 2004 Jul;56(7):827-40. doi: 10.1211/0022357023691.
9
Aerosol generation by metered-dose inhalers containing dimethyl ether/propane inverse microemulsions.
AAPS PharmSciTech. 2003 Nov 26;4(4):E58. doi: 10.1208/pt040458.
10
Fluorinated ionic surfactant microemulsions in hydrofluorocarbon 134a (HFC 134a).
J Colloid Interface Sci. 2003 Feb 15;258(2):354-62. doi: 10.1016/s0021-9797(02)00071-1.
Zotero 插件